Salarius Pharmaceuticals Inc (SLRX)

NASDAQ
1.17
+0.02(+1.74%)
After Hours
1.18
+0.01(+0.855%)
- Real-time Data
  • Volume:
    1,578,921
  • Bid/Ask:
    1.17/1.18
  • Day's Range:
    1.14 - 1.20

SLRX Overview

Prev. Close
1.15
Day's Range
1.14-1.2
Revenue
5.37M
Open
1.16
52 wk Range
0.632-3.45
EPS
-0.42
Volume
1,578,921
Market Cap
52.34M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,609,865
P/E Ratio
-
Beta
1.59
1-Year Change
-23.53%
Shares Outstanding
44,734,328
Next Earnings Date
Aug 18, 2021
What is your sentiment on Salarius Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Salarius Pharmaceuticals Inc News

Salarius Pharmaceuticals Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellSellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong BuyStrong SellSell
SummaryStrong SellStrong SellNeutralStrong SellStrong Sell

Salarius Pharmaceuticals Inc Company Profile

Salarius Pharmaceuticals Inc Company Profile

Employees
9

Salarius Pharmaceuticals, Inc., formerly Flex Pharma, Inc., is a clinical-stage oncology company. The Company is developing targeted therapies to treat pediatric and other cancers, including solid tumors. The Company is targeting the epigenetic causes of cancers and is developing treatments for patients. The Company’s lead candidate, Seclidemstat, is a reversible lysine specific histone demethylase 1 (LSD1) inhibitor. Seclidemstat is in phase I clinical study for treating Ewing sarcoma. Seclidemstat inhibits LSD1's demethylation and scaffolding properties, representing a therapeutic option for patients who need it. The Company is also developing Seclidemstat for a number of cancers with unmet need, with a clinical study in solid tumors including, prostate, breast and ovarian cancers.

Read More
  • the stock falls but before December 21 will hopefully think that it raises to $15
    0
    • someday some good news is going come out, and this stock it's going to shoot up hundreds of percents
      1
      • yes
        0
    • is this a scam stock
      2
      • there are many big guys on it, i can't say for sure but i seems improbable to me
        0
    • hmmm..if it drops to sub $2 before close maybe tomorrow could bring $3 with some post and premarket push
      1
      • My interpretation of the digital meeting held today with investors is that this is a very potential trigger for increase.
        0
    • http://investors.salariuspharma.com/news-releases/news-release-details/salarius-pharmaceuticals-present-diamond-equity-research Sounds to me like this Stock problary will increase futher after today? After this meeting with investors
      0
      • Moving to phase 2 of testing today with seclidemstat & will look to announce recent findings soon. Good signs.
        0
        • The stock is tanking today how come ?
          0
          • toidi people selling
            0
        • Buying more :)
          0
          • Expecting an increase past $4
            0
            • https://www.macroaxis.com/valuation/bbi/brickell-biotech
              0
              • I'd not be impressed if it becomes a 30 dollar stock at the end of this year
                0
                • i am trying to invest in this but am unable to find on my current client, anyone can put me towards right place?
                  0
                  • i use tastyworks
                    0
                • biolase!! going up
                  0
                  • and to boot I bought at 65 cents now it's at 11$ and I can't sell because?
                    0
                    • no longer tradable yet strong buy....
                      5
                      • I'm just here for the ride. I've actually been to this place before and I can see why they're taking off this much. I'm happy for them.
                        0
                        • I heard that there is merger of FLKS pharma with other pharma. when this going to happen and is there is any benefit to keep this stock for that long?
                          0
                          • me like FLKS
                            0
                            • What's happening with Flex? Keep draining share value. I am stuck. Any suggestions?
                              5
                              Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                              Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.